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ABSTRACT: Establishing structure−activity relationships
(SARs) in hit identiﬁcation during early stage drug discovery
is important in accelerating hit conﬁrmation and expansion.
We describe the development of EnCore, a systematic
molecular scaﬀold enumeration protocol using single atom
mutations, to enhance the application of objective scaﬀold
deﬁnitions and to enrich SAR information from analysis of
high-throughput screening output. A list of 43 literature
medicinal chemistry compound series, each containing a
minimum of 100 compounds, published in the Journal of
Medicinal Chemistry was collated to validate the protocol. Analysis using the top representative Level 1 scaﬀolds this list of
literature compound series demonstrated that EnCore could mimic the scaﬀold exploration conducted when establishing SAR.
When EnCore was applied to analyze an HTS library containing over 200 000 compounds, we observed that over 70% of the
molecular scaﬀolds matched extant scaﬀolds within the library after enumeration. In particular, over 60% of the singleton
scaﬀolds with only one representative compound were found to have structurally related compounds after enumeration. These
results illustrate the potential of EnCore to enrich SAR information. A case study using literature cyclooxygenase-2 inhibitors
further demonstrates the advantage of EnCore application in establishing SAR from structurally related scaﬀolds. EnCore
complements literature enumeration methods in enabling changes to the physicochemical properties of molecular scaﬀolds and
structural modiﬁcations to aliphatic rings and linkers. The enumerated scaﬀold clusters generated would constitute a
comprehensive collection of scaﬀolds for scaﬀold morphing and hopping.
■ INTRODUCTION
Establishing the relationships between molecular structures and
their modulatory activity against biological targets of interest
represents an essential activity of medicinal chemistry in drug
discovery. Structure−activity relationship (SAR) information
correlates chemical structures with important parameters
during hit- and lead-optimization, including both physicochem-
ical properties of and biological responses to ligand molecules.
Its widespread application to understand quantitatively the
biological eﬀects of chemical structural modiﬁcations and the
development of predictive models from SAR information are
collectively referred to as quantitative SAR (QSAR).
High-throughput screening (HTS) represents a common hit
discovery activity in early stage drug discovery.1 SAR
information is often cumulatively enriched when screening-hit
matter is progressed toward a clinical candidate through various
strategies such as analog-by-catalog, structure-based molecular
design, and array chemistry. However, it would be desirable to
derive SAR information during the hit discovery stage when
classifying hit matter into clusters of compound series. Such
SAR would further inform prioritization for hit selection and
hit-to-lead activities.
To establish SAR, it is often necessary to deﬁne suitable
representations of the chemical series that is relevant to the
majority of the compounds synthesized and tested, commonly
referred to as a molecular scaﬀold.2−4 Substituents attached to
such deﬁned scaﬀolds represent structural variants that can be
correlated to observed property changes. Objective scaﬀold
representations such as the Murcko framework5 and the
Scaﬀold Tree classiﬁcation2 have been reported. Such scaﬀold
deﬁnitions are data set independent, and allow for easy
interpretation by expert chemists, hence are commonly applied
in establishing SAR information.4,6,7 In addition, objective
scaﬀold deﬁnitions have also been applied in assembling
screening libraries8,9 and analyzing chemical space of fragment
screening.10
The application of objective scaﬀold deﬁnitions in clustering
screening hits represents a structure-oriented approach to
understand the SAR of HTS data. Screening compounds that
share the same molecular scaﬀold can be clustered together and
SAR information can be readily derived. This approach can
quickly identify compound clusters with promising screening
results that can be prioritized for further hit-to-lead studies. On
the contrary, clustering methods such as molecular ﬁngerprint
similarity clustering11 and HTS ﬁngerprints12 may cluster
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together molecules of low structural resemblance to each other,
which may hinder the assembly of SAR information when
prioritizing compound series and developing medicinal
chemistry design strategies. Nonetheless, objective scaﬀold
deﬁnitions may sometimes be too stringent and result in
molecular scaﬀolds that are only represented by single
exemplars without revealing other structural analogs in a
screening library. These “singleton” scaﬀolds may be more
challenging for hit conﬁrmation and expansion,13 and may
often be deprioritized when shortlisting screening-hit matter for
hit-to-lead activity.
To enhance the application of objective scaﬀold deﬁnitions in
HTS compound clustering and triaging, it would be beneﬁcial
to introduce some controlled fuzziness in the molecular scaﬀold
representation that is structurally relevant and interpretable for
synthetic medicinal chemistry. Literature publications have
reported the utilization of molecular enumeration methods in
designing medicinal chemistry reagents,14 enhancing de novo
and structure-based molecular design15,16 and exploring
heterocyclic regioisomers (HREMS).17 Herein, we report the
development of EnCore, an enumeration approach based upon
molecular core scaﬀolds, that incorporates single atom
mutations by systematically introducing elemental atom
changes within a deﬁned molecular scaﬀold. The mutated
scaﬀolds represent structurally related scaﬀolds to the parent
scaﬀold and are grouped in an enumerated scaf fold cluster. The
method is validated using medicinal chemistry compound series
derived from the literature and the DrugBank approved drugs
data set to demonstrate its relevance to medicinal chemistry
molecular design. Its application in enriching SAR information
was investigated using an in-house compound library designed
for HTS and a case study of literature cyclooxygenase-2 (COX-
2) inhibitors.
■ MATERIALS AND METHODS
EnCore Molecular Scaﬀold Enumeration. The canonical
representation of the input molecular scaﬀold in simpliﬁed
molecular-input line-entry system (SMILES) format is used for
enumeration implemented using Pipeline Pilot client v9.5.18
Any explicit hydrogen atoms in the canonical SMILES are
removed prior to enumeration. Carbon, nitrogen, and oxygen
atoms within an input SMILES, including all aromatic rings,
aliphatic rings, and structural linkers, are interchangeable to
either of the other two elements, and a single atom change is
allowed per mutation. In each generation, all single atom
mutations are generated. The mutated SMILES are then
converted to molecular representation and the mutated
scaﬀolds are checked for valid valence. Sulfur atom mutation
was not included in the default parameters since many of the
sulfur mutations produced scaﬀolds that violated the valence
check. Mutated scaﬀolds violating the valence check are
removed before the number of aromatic atoms in the mutated
scaﬀold is compared to the parent scaﬀold. Any mutated
scaﬀolds with a diﬀerent number of aromatic atoms (i.e., a
single atom mutation would violate the Hückel’s rule of
aromaticity)19 are removed. This aromaticity check is analogous
to that described in the MORPH algorithm that only alters
aromatic ring species in an input molecule.15 Finally, any
duplicate mutated scaﬀolds are removed. All unique mutated
scaﬀolds within the same enumerated scaﬀold cluster are used
for the next generation of mutations (Figure 1). Figure 2 shows
two exemplary EnCore enumerated scaﬀold clusters of
imidazole and 3-(4H-1,2,4-triazolo-4-yl)pyridine.
Literature Medicinal Chemistry Series. ChEMBL2120
was mined for compound series reported in the Journal of
Medicinal Chemistry. To ensure reasonable chemical space has
been explored for the selected series, each series was required
to contain a minimum of 100 compounds in a single
publication, with reported IC50 values against a deﬁned
molecular target. 62 publications satisfying these criteria were
retrieved. Inspection of this publication shortlist removed 19
publications that did not focus on synthetic medicinal
chemistry designs (e.g., publications on virtual screening,
CoMFA/QSAR analyses of literature compounds, model
developments and reviews). The top Level 1 scaﬀold, deﬁned
as the Scaﬀold Tree Level 1 scaﬀold2,13 representing the largest
number of compounds within the series, in each of the
remaining 43 publications were enumerated (see Supporting
Information Table S1 for the list of publications and their top
Level 1 scaﬀolds). All other Level 1 scaﬀolds explored within
each series were then compared to the mutated scaﬀolds output
in the corresponding enumerated scaﬀold cluster.
DrugBank Data Set. Here, 1826 compounds from the
DrugBank approved drugs data set were analyzed.21 After
stripping salts, 962 compounds compliant with Lipinski’s rule-
of-ﬁve22 and containing at least two rings were retained to
generate 475 unique Level 1 scaﬀolds using the Pipeline Pilot
component Generate Scaf fold Tree.18 The data set of unique
Level 1 scaﬀolds was used for scaﬀold enumeration. EPFP7
ﬁngerprints (extended path ﬁngerprint with a distance of seven
bonds), analogous to the Daylight molecular ﬁngerprints,23,24
were generated using Pipeline Pilot18 and the mutated scaﬀolds
were compared to their parent scaﬀold. The mutated scaﬀold
with the highest Tanimoto ﬁngerprint similarity to the parent
Figure 1. EnCore systematic molecular scaﬀold enumeration workﬂow.
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scaﬀold and the average Tanimoto ﬁngerprint similarity of all
mutated scaﬀolds per generation were used to evaluate the
scaﬀold diversity of the enumerated scaﬀold clusters over
generations.
ICR/CRT Screening Library Data Set. The Institute of
Cancer Research/ Cancer Research Technology (ICR/CRT)
in-house hit discovery screening collection, containing 214 540
compounds, was used as an HTS library data set. Level 1
scaﬀolds were generated for 214 540 compounds using Pipeline
Pilot component Generate Scaf fold Tree.18 23 319 unique Level
1 scaﬀolds were generated. 11 662 of these scaﬀolds had only
one representative screening compound (singleton scaﬀold).
All unique Level 1 scaﬀolds were used to generate enumerated
scaﬀold clusters.
Literature Cyclooxygenase-2 (COX-2) Inhibitors Data
Set. All small molecules with reported IC50 values against
cyclooxygenase-2 (COX-2) published in the Journal of
Medicinal Chemistry were retrieved using ChEMBL21.20 Level
1 scaﬀolds were generated for the 1289 unique compounds
retrieved from 93 publications (see Supporting Information
Table S2 for the list of publications). Where a molecule has
multiple IC50 values reported in multiple publications, the
highest value corresponding to weakest COX-2 inhibition was
retained.
■ RESULTS AND DISCUSSION
To validate the EnCore scaﬀold enumeration protocol, we ﬁrst
investigated its relevance to medicinal chemistry molecular
design using the literature medicinal chemistry series data set.
The protocol was then applied to the DrugBank data set to
deﬁne a rule-of-thumb for the number of generations of
enumeration. After these criteria are deﬁned, the application of
EnCore scaﬀold enumeration in enriching SAR information was
investigated using the ICR/CRT library as an HTS compound
data set. The capability of EnCore scaﬀold enumeration in
increasing the number of structurally related compounds
associated with each scaﬀold was analyzed. Finally, a case
study of literature COX-2 inhibitors was used to illustrate the
advantage of EnCore applications in enriching SAR information
from structurally related scaﬀolds.
All experiments presented here used the Level 1 scaﬀolds
generated following the Scaﬀold Tree algorithm that system-
atically deconstructs molecules based on ring-focused dis-
Figure 2. Exemplary EnCore enumerated scaﬀold clusters of (a)
imidazole and (b) 3-(4H-1,2,4-triazolo-4-yl)pyridine. Scaﬀold gen-
erations are illustrated in diﬀerent colored backgrounds: parent
scaﬀold (red), ﬁrst generation mutated scaﬀolds (orange), and second
generation mutated scaﬀolds (yellow).
Figure 3. (a) Number of Level 1 scaﬀolds within the 43 literature medicinal chemistry compound series against the number of compounds within
the series. (b) Breakdown of the generation of enumerations in which additional Level 1 scaﬀolds explored within the same compound series were
identiﬁed using the enumerated scaﬀold clusters. For some compound series, multiple Level 1 scaﬀolds reported in the publication matched the
enumerated scaﬀolds in multiple generations.
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connection rules.2 In a recent publication on the scaﬀold
diversity of exempliﬁed medicinal chemistry,13 it was observed
that Level 1 of the Scaﬀold Tree typically represents an
appropriate objective and invariant scaﬀold deﬁnition. We
therefore utilizes the Level 1 scaﬀolds as the scaﬀold
representation to illustrate the features of EnCore applications.
Theoretically, to exhaustively generate all possible mutated
scaﬀolds of an input scaﬀold, the enumeration protocol by
deﬁnition needs to compile as many generations as the number
of heavy atoms in the molecular scaﬀold. As the size of the
enumerated scaﬀold cluster increases over generations, the
number of mutated scaﬀolds increases, thereby increasing the
time required to generate these mutations. Therefore, it is
necessary to evaluate the number of unique mutated scaﬀolds
generated and their structural diversity per generation in
comparison to the parent scaﬀold, and deﬁne a balance between
the time required to generate mutated scaﬀolds and the
increase in chemical space sampled by the mutated scaﬀolds.
The following two experiments analyze the relevance of
EnCore to medicinal chemistry and the structural diversity of
the mutated scaﬀolds over generations, respectively. We apply
our results to validate the EnCore protocol and to deﬁne the
optimal number of enumeration generations as a rule-of-thumb
for EnCore applications.
Relevance to Medicinal Chemistry Molecular Design.
One of the potential applications of EnCore aims to mimic the
exploration of molecular scaﬀolds when developing SAR in a
drug discovery program. To demonstrate that EnCore is
relevant for medicinal chemistry molecular design, published
compound series from the medicinal chemistry literature were
analyzed. This was facilitated by mining the ChEMBL
database25 to identify compound series published in the Journal
of Medicinal Chemistry that are likely to originate from a
medicinal chemistry program.
Figure 3a shows the homogeneity of the 43 collated literature
compound series investigated, by plotting the number of
unique Level 1 scaﬀolds against the total number of compounds
within each series. This data set represents a diverse proﬁle of
medicinal chemistry compound series, from homogeneous
series containing only one scaﬀold representing the entire series
of 200 compounds published in one paper, to heterogeneous
series represented by over 30 Level 1 scaﬀolds. Out of the 43
input scaﬀolds, 23 enumerated scaﬀold clusters were successful
in identifying Level 1 scaﬀolds explored within the same
compound series, i.e. the mutated scaﬀolds generated in the
enumerated scaﬀold clusters matched other Level 1 scaﬀolds
reported in their respective publication. For some compound
series, multiple Level 1 scaﬀolds reported in the publication
matched the enumerated scaﬀolds in multiple generations. The
Figure 4. Box-and-whisker plots of distributions of mutated scaﬀolds from the DrugBank approved drugs data set. (a) Number of new molecular
scaﬀolds obtained from scaﬀold enumeration over four generations of mutations. (b) Average Tanimoto ﬁngerprint similarity (EPFP7) of the
mutated scaﬀolds to the parent scaﬀold per generation of mutations. (c) Tanimoto ﬁngerprint similarity (EPFP7) of the mutated scaﬀolds most
similar to their respective parent scaﬀolds per generation of mutations.
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breakdown of the generation of enumerations where other
Level 1 scaﬀolds were matched is shown in Figure 3b. For 20
compound series, mutated scaﬀolds in the ﬁrst generation could
match other explored molecular scaﬀolds within the series; for
nine series, their second generation mutated scaﬀolds identiﬁed
additional molecular scaﬀolds within the series, whereas only
two compound series have mutated scaﬀolds in the third and
fourth generations that matched any explored molecular
scaﬀolds.
The observations in Figure 3 support the hypothesis that the
enumerated scaﬀold clusters can identify additional molecular
scaﬀolds that have been explored within the same compound
series reported in literature medicinal chemistry programs.
Even though only a subset of the enumerated scaﬀold clusters
could match explored molecular scaﬀolds reported (23 out of
43 compound series), the results here suggest that EnCore can
partially mimic the exploration of molecular scaﬀolds when
developing SAR in medicinal chemistry projects.
Structural Diversity of the Mutated Scaﬀolds over
Generations. To further assist deﬁning the optimal number of
enumeration generations as a rule-of-thumb for EnCore
applications, the number of unique mutated scaﬀolds generated
and their structural diversity were assessed using the Level 1
scaﬀolds derived from the DrugBank approved drugs data set.21
Figure 4a shows the box-and-whisker plots of the distribution of
the number of unique mutated scaﬀolds generated from the
475 DrugBank Level 1 scaﬀolds per generation. The median
number of unique mutated scaﬀolds generated is 12 in the ﬁrst
generation, increasing to 65 in the second, 210 in the third, and
448 in the fourth generations. Since the average number of
heavy atoms in the parent Level 1 scaﬀolds for the entire
DrugBank data set is 12 ± 3, the increase in the number of
unique mutated scaﬀolds per generation observed is not
surprising. It is noteworthy that some of the outliers in the
fourth generation, reaching over 10 000 unique mutated
scaﬀolds, originated from parent scaﬀolds with greater than
25 heavy atoms exempliﬁed by two rings connected by a very
long alkyl chain.
EPFP7 ﬁngerprints, analogous to the Daylight molecular
ﬁngerprints,10,23,24 were used to assess the structural diversity of
the unique mutated scaﬀolds in comparison to their parent
scaﬀold per generation. Figure 4b shows the average Tanimoto
ﬁngerprint similarity for all unique mutated scaﬀolds to their
respective parent scaﬀold per generation, whereas Figure 4c
shows the Tanimoto ﬁngerprint similarity of the mutated
scaﬀold most similar to its parent scaﬀold per generation. From
these plots, it can be observed that the structural similarity of
the unique mutated scaﬀolds to their parent scaﬀolds decreases
sharply over generations, with the median of the distribution at
only 0.46 in the ﬁrst generation when considering the average
of all unique mutated scaﬀolds generated, and below 0.3
beyond the second generation. Even when considering the
most similar mutated scaﬀold in each generation, the median
ﬁngerprint similarity value drops below 0.6 after two
generations of mutations. All the median values fall below the
threshold Tanimoto similarity cutoﬀ of 0.85, above which any
molecular pairs may be considered chemically similar.24
Together with the analysis on literature medicinal chemistry
compound series, it can be concluded from these two
experiments that two generations of enumeration is a
reasonable balance between chemical space sampling and the
likelihood of the mutated scaﬀolds within the enumerated
scaﬀold cluster having been explored in medicinal chemistry.
All further EnCore applications described within this paper will
refer to two generations of enumerations as the optimal
number deﬁned here.
Relevance to Enriching SAR in HTS Library. To
demonstrate the applicability of EnCore in enriching SAR, we
Figure 5. Heat maps showing (a) the number of matched extant scaﬀolds after scaﬀold enumeration plotted against the original number of screening
compounds represented by the parent Level 1 scaﬀolds within the ICR/CRT screening library (n = 23 319). The color key shows the density of
unique parent scaﬀolds that have recorded the same number of matched extant scaﬀolds after enumeration. (b) The number of matched extant
scaﬀolds plotted against the number of structurally related screening compounds associated after scaﬀold enumeration for all singleton scaﬀolds
within the ICR/CRT screening library (n = 11 662). The color key shows the density of unique parent scaﬀolds in each bin.
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evaluated a screening library that has been designed for HTS
applications. When conducting an HTS, it is common practice
to quickly identify hit series that both deliver the desirable
biological responses and indicate initial SAR to guide medicinal
chemistry molecular design. However, commonly, SAR
information from primary HTS output can be limited; for
example, when a screening hit is classiﬁed as a “singleton”
where no structurally related analogs are represented within the
library.
Using the ICR/CRT screening library containing over
200 000 compounds, we explored the application of EnCore
to enrich SAR information by classifying the library compounds
into multiple enumerated scaﬀold clusters. Enumerated
scaﬀolds for each individual parent scaﬀold were compared to
other extant scaﬀolds present in the screening library. A match
between extant scaﬀolds and those within the enumerated
scaﬀold cluster of the parent scaﬀold would indicate an increase
in the number of structurally related screening compounds
associated with that particular parent scaﬀold, hence the
possibility of enriching SAR information.
All 23 319 Level 1 scaﬀolds from the entire ICR/CRT
screening library were enumerated over two generations and
the enumerated scaﬀold clusters were assessed. Figure 5a shows
a heat map indicating the number of molecular scaﬀolds after
enumeration against the original number of screening
compounds associated with each parent scaﬀold in the
screening library. Each bin in the heat map contains a
population of unique parent scaﬀolds that recorded the same
number of matched extant scaﬀolds after enumeration, and the
color key represents the density of parent scaﬀolds in each bin.
Out of the 23 319 parent scaﬀolds, extant scaﬀolds within the
screening library have been identiﬁed in the enumerated
Figure 6. Expansion of SAR in COX-2 inhibitors is enabled through applying EnCore scaﬀold enumeration. (a) Top Level 1 scaﬀold, 5-phenyl-1H-
pyrazole (1), identiﬁed in the COX-2 inhibitors published by Penning et al.26 (b−d) Distribution of the COX-2 pIC50 values (b) from the inhibitors
published originally (n = 43) and structurally related inhibitors retrieved from ChEMBL21 (n = 357); (c) grouped by generations of mutated
scaﬀolds (n = 357); and (d) grouped by individual Level 1 scaﬀolds (n = 357). Numbers in pie charts correspond to compound count in each pIC50
range category unless stated otherwise. Numbers in pie charts in part d correspond to compound count represented by each scaﬀold.
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scaﬀold clusters of 17 199 scaﬀolds, whereas the remaining
6120 scaﬀolds (the bottom row in the heat map in Figure 5a)
did not match any extant scaﬀolds after enumeration. Two
parent scaﬀolds had the largest number of matched extant
scaﬀolds in their enumerated scaﬀold clusters, matching 54
extant scaﬀolds representing 3976 screening compounds in
total. Since each of these two parent scaﬀolds represent only
around 50 screening compounds individually, the increase in
the number of screening compounds associated with these
parent scaﬀolds after EnCore application represents a substantial
expansion of structurally related compounds within the
screening library for which SAR information may be readily
available.
Another striking observation is that out of the 11 662
singleton parent scaﬀolds (the leftmost column in the heat map
in Figure 5a), 7369 parent scaﬀolds matched with extant
scaﬀolds after EnCore enumeration. This indicates that
structurally related screening compounds within the library
can be associated with over 60% of the singleton scaﬀolds that
each represent only one screening compound. Since by
deﬁnition the compounds in these singleton scaﬀolds have no
structural analogs sharing the same molecular scaﬀold, the
application of EnCore identiﬁes structurally related analogs and
enhances the possibility of obtaining readily available SAR
information from within the screening library. A more detailed
heat map for singleton scaﬀolds (Figure 5b) shows the number
of matched extant scaﬀolds against the number of screening
compounds after EnCore enumeration. This further illustrates
that many singleton scaﬀolds have a substantial increase in the
number of structurally related screening compounds after
EnCore enumeration. Two singleton scaﬀolds have over 10 000
screening compounds associated after EnCore enumeration,
represented by 21 and 43 extant scaﬀolds (the rightmost
column in the heat map in Figure 5b).
Case Study Using Literature COX-2 Inhibitors. To
demonstrate the expansion of SAR enabled through applying
EnCore scaﬀold enumeration in HTS data analysis, literature
COX-2 inhibitors were retrieved and analyzed as a simulated
screening data set.
In the literature medicinal chemistry series collated, the 5-
phenyl-1H-pyrazole scaﬀold 1 (Figure 6a) was identiﬁed as the
top Level 1 scaﬀold representing 43 compounds in the COX-2
inhibitors published by Penning et al.26 Its enumerated scaﬀold
cluster after two generations of EnCore enumeration contains
71 unique scaﬀolds (Table S1). 1289 unique compounds with
reported IC50 values against COX-2 published in 93 Journal of
Medicinal Chemistry publications were retrieved from
ChEMBL21 (Table S2). Eleven Level 1 scaﬀolds, representing
357 unique compounds out of the 1289 COX-2 inhibitors
retrieved, matched scaﬀolds in the EnCore enumerated scaﬀold
cluster from 1. Figure 6b compares the distribution of the pIC50
values among the 43 compounds originally published in
Penning et al.26 and the expanded list of 357 compounds
retrieved using the EnCore enumerated scaﬀold cluster. The
number of compounds with COX-2 pIC50 ≥ 6 increased from
31 to 180 compounds, whereas the number of weak inhibitors
with COX-2 pIC50 < 4 also increased from one to 79
compounds. These observations illustrate that SAR information
can be readily enriched from compounds with structurally
related scaﬀolds as a result of applying EnCore scaﬀold
enumeration.
Grouped by generations of mutated scaﬀolds (Figure 6c), 80
compounds (57 with COX-2 pIC50 ≥ 6) are represented by the
parent scaﬀold 1, whereas 121 compounds (64 with COX-2
pIC50 ≥ 6) are represented by ﬁrst generation mutated scaﬀolds
and another 156 compounds (59 with COX-2 pIC50 ≥ 6) are
represented by second generation mutated scaﬀolds in the
enumerated scaﬀold cluster. Further analysis of these 357
compounds by individual Level 1 scaﬀolds (Figure 6d)
suggested that many of the 153 analogs represented by the 2-
phenyl-1H-pyrrole 2 and 5-phenyl-1H-imidazole 6 scaﬀolds
could inhibit COX-2, whereas the majority of the 84 analogs
represented by 2-phenyl-1H-imidazole 5 were inactive against
COX-2 (74 with COX-2 pIC50 < 4). This demonstrates the
advantage of EnCore application in instantly establishing SAR
information from structurally related scaﬀolds. Although this is
a retrospective analysis of published COX-2 inhibitors, this
method is also applicable to prospective analysis, for instance,
of compound screening data from an HTS campaign.
Our analyses of literature medicinal chemistry compound
series and an HTS library illustrate two potential applications of
EnCore to enable medicinal chemistry design by enriching SAR
information. Using the top Level 1 scaﬀolds in the 43 literature
medicinal chemistry compound series retrieved from the
Journal of Medicinal Chemistry, EnCore is able to identify
other explored scaﬀolds within the same publication for 23
series. This satisﬁes one of the aims of developing EnCore to
enrich SAR information in medicinal chemistry molecular
design.
Although our molecular scaﬀold diversity analysis suggests an
optimum of two generations of mutations as a default setup,
EnCore can generate multiple generations of mutated scaﬀolds
if the enumerated scaﬀold clusters require broader diversity
from the parent scaﬀold. The protocol can theoretically
enumerate as many generations of mutated scaﬀolds as the
number of heavy atoms in the scaﬀold. The resultant
enumerated scaﬀold cluster constitutes a comprehensive
collection of structurally related molecular scaﬀolds for scaﬀold
morphing and hopping.15,27 In comparison to manual
molecular scaﬀold designs, the enumerated scaﬀold cluster
would be advantageous in removing potential bias against less
common but structurally feasible molecular scaﬀolds, whereas
synthetically intractable molecular scaﬀolds may stimulate the
development of innovative synthetic methods.28
Our experimental observations from enumerating molecular
scaﬀolds of the HTS library oﬀer interesting insights into the
classiﬁcation of compounds into structurally related enum-
erated scaﬀold clusters. While various methods of compound
clustering have been extensively applied in SAR analyses,
EnCore oﬀers a comprehensive method to identify structurally
related analogs that are relevant to SAR exploration.
Structurally related screening compounds within the library
can be associated with over 60% of the singleton scaﬀolds after
molecular scaﬀold enumeration. Analogously, over 70% of all
the scaﬀolds in the compound library matched extant scaﬀolds
within the library after enumeration. Even though the increase
in the number of screening compounds diﬀers for each parent
scaﬀold, the results demonstrated that EnCore can readily
identify screening compounds containing structurally related
molecular scaﬀolds to enrich SAR information from HTS
output. The ability of EnCore application in enriching SAR
information was further demonstrated in the case study using
literature COX-2 inhibitors, where molecules represented by
structurally related scaﬀolds could be readily compared to
identify favorable and to deprioritize unfavorable scaﬀolds for
COX-2 inhibition. While objective scaﬀold deﬁnition is
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certainly structurally intuitive and easily interpretable, a major
drawback of its application in analyzing HTS output is that it
may introduce a sizable population of structural singletons that
are considered unfavorable for hit conﬁrmation and expan-
sion.13 However, when applied in conjunction with the
molecular scaﬀold enumeration approach, we demonstrate
that SAR information can be readily enriched. This approach
will also be useful when selecting a subset of structurally related
molecules as prioritized representatives of a large screening
collection, and when designing compound libraries where
structurally related compounds can be incorporated to enhance
intrinsic SAR within a screening collection.
EnCore is complementary to literature enumeration tools. In
comparison to the literature regioisomer enumeration tool
HREMS,17 EnCore allows changes to the physicochemical
properties of the molecular scaﬀold such as topological polar
surface area when introducing heteroatom changes, which can
be beneﬁcial in molecular scaﬀold design and optimization. The
method here is not limited to aromatic heterocycles, as opposed
to the literature MORPH algorithm,15 hence capturing
additional design ideas that introduce changes to aliphatic
ring systems and structural linkers in molecular scaﬀolds.
■ CONCLUSIONS
Establishing SAR in hit identiﬁcation during early stage drug
discovery is important in accelerating hit conﬁrmation and
expansion. While the application of objective scaﬀold
deﬁnitions in analyzing HTS output can assist in achieving
this goal, its stringent deﬁnitions may result in singleton
scaﬀolds being deprioritized. To enhance the application of
objective scaﬀold deﬁnitions in establishing SAR, a systematic
molecular scaﬀold enumeration approach EnCore has been
developed to enrich SAR information.
Using the top Level 1 scaﬀolds in the literature medicinal
chemistry compound series retrieved from the Journal of
Medicinal Chemistry, EnCore was able to match additional
molecular scaﬀolds explored within the same compound series.
This demonstrates that EnCore could mimic the scaﬀold
exploration conducted when establishing SAR in a drug
discovery program.
In addition, the enumerated scaﬀold clusters constitute a
comprehensive collection of scaﬀolds for scaﬀold morphing and
hopping when designing new molecules. Since EnCore
enumerates all possible mutations over generations, potential
bias against less common but structurally feasible molecular
scaﬀolds is minimized, whereas synthetically intractable
molecular scaﬀolds may stimulate the discovery of innovative
synthetic methods.
When EnCore was applied in conjunction with objective
scaﬀold deﬁnitions to the analysis of an HTS library, an
enrichment in readily available SAR information was demon-
strated. Over 70% of the molecular scaﬀolds observed an
increase in the number of structurally related screening
compounds associated with each scaﬀold after enumeration.
In particular, over 60% of the singleton scaﬀolds with only one
representative compound were found to have structurally
related compounds after enumeration. This will be particularly
useful in expanding design opportunities when encountering
structural singletons during hit identiﬁcation.
EnCore oﬀers additional capabilities to literature enumeration
tools including changes to the physicochemical properties of
molecular scaﬀolds and structural modiﬁcations to aliphatic
rings and linkers. This oﬀers a complementary tool for
molecular scaﬀold exploration in medicinal chemistry to
establish and enrich SAR information.
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